A collection of studies presented at a recent American Heart Association (AHA) conference has confirmed the heart health benefits provided by the new anti-obesity drugs, semaglutide and tirzepatide, ...

In a new analysis of national data, researchers at the Richard A. and Susan F. Smith Center for Outcomes Research at Beth ...

So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays ...

(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 in ...

GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

After a median follow-up of 5.9 years, no effect was observed in the ‘time to first occurring composite endpoint’ (HR 1.0; 95 ...

Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...

The "Diabetes - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Diabetes - Pipeline Insight, 2024" report provides comprehensive insights about 200+ ...

The "Type 2 Diabetes - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 75+ companies and 80+ pipeline drugs ...

Natural products industry companies share overviews on the latest science on their branded ingredients to support wellbeing.

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...